DaVita Inc. (NYSE:DVA) Shares Sold by Bridgewater Associates LP

Bridgewater Associates LP cut its holdings in shares of DaVita Inc. (NYSE:DVA) by 25.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 60,226 shares of the company’s stock after selling 20,472 shares during the quarter. Bridgewater Associates LP owned about 0.07% of DaVita worth $9,873,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. lifted its holdings in shares of DaVita by 29.6% during the 2nd quarter. Assenagon Asset Management S.A. now owns 50,096 shares of the company’s stock worth $6,942,000 after acquiring an additional 11,454 shares during the period. Comerica Bank boosted its holdings in shares of DaVita by 41.4% in the 1st quarter. Comerica Bank now owns 34,431 shares of the company’s stock valued at $4,753,000 after purchasing an additional 10,074 shares during the last quarter. Quest Partners LLC purchased a new stake in shares of DaVita during the 3rd quarter valued at $669,000. MBB Public Markets I LLC acquired a new stake in shares of DaVita during the 2nd quarter worth $582,000. Finally, Chase Investment Counsel Corp increased its holdings in shares of DaVita by 56.3% during the 3rd quarter. Chase Investment Counsel Corp now owns 33,084 shares of the company’s stock worth $5,423,000 after buying an additional 11,912 shares during the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

DVA has been the subject of a number of research reports. Barclays boosted their price target on DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Truist Financial boosted their target price on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a report on Monday, October 7th. UBS Group raised their price target on shares of DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 8th. Finally, Bank of America boosted their price objective on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, DaVita has a consensus rating of “Hold” and an average price target of $161.80.

Insider Buying and Selling

In other news, CEO Javier Rodriguez sold 50,000 shares of the firm’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the completion of the sale, the chief executive officer now directly owns 837,835 shares in the company, valued at $138,284,666.75. This trade represents a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.00% of the stock is currently owned by insiders.

DaVita Stock Performance

Shares of NYSE:DVA opened at $165.63 on Friday. The business’s 50-day simple moving average is $158.47 and its 200 day simple moving average is $148.99. The company has a market cap of $13.58 billion, a P/E ratio of 17.87, a PEG ratio of 0.93 and a beta of 0.89. The company has a debt-to-equity ratio of 15.78, a quick ratio of 1.33 and a current ratio of 1.37. DaVita Inc. has a one year low of $98.26 and a one year high of $169.51.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). The firm had revenue of $3.26 billion for the quarter, compared to analysts’ expectations of $3.25 billion. DaVita had a net margin of 6.53% and a return on equity of 88.18%. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.85 EPS. On average, sell-side analysts forecast that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.